Forecast Of The Day: Pfizer’s Oncology Revenue

PFE: Pfizer logo


Pfizer’s (NYSE:PFE) Oncology Revenue, which includes revenues from Sutent, Xalkori, Inlyta, Ibrance, and other productions, rose from around $9 billion in 2019 to about $11 billion in 2020. We expect the metric to rise to around $12.6 billion in 2021 and $13.6 billion in 2022.


Relevant Articles
  1. Should You Buy Pfizer Stock After An Upbeat Q2?
  2. Should You Buy Pfizer Stock Ahead of Its Q2 Results?
  3. Should You Buy, Sell, Or Hold Pfizer Stock At $52?
  4. Here’s A Better Pick Over FedEx Stock
  5. Company Of The Day: Pfizer
  6. What To Expect From Pfizer’s Q1?

Growth is being driven by market share gains for Ibrance, as well as the launch of new biosimilars.

So What?

We think the projected growth is largely priced into PFE stock. We value Pfizer at about $58 per share, roughly in line with the current market price.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

 Returns Jan 2022
MTD [1]
YTD [1]
Total [2]
 PFE Return -6% -6% 71%
 S&P 500 Return -2% -2% 108%
 Trefis MS Portfolio Return -7% -7% 265%

[1] Month-to-date and year-to-date as of 1/13/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates